

NOVADEL PHARMA INC

Form 8-K

June 02, 2011

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) June 2, 2011

NOVADEL PHARMA INC.  
(Exact Name of Registrant as Specified in Its Charter)

Delaware (State or other jurisdiction of incorporation or organization)	001-32177 (Commission File No.)	22-2407152 (I.R.S. Employer Identification No.)
--	------------------------------------	---

1200 Route 22 East, Suite 2000  
Bridgewater, NJ 08807  
(Address of principal executive offices) (Zip Code)

(908) 203-4640  
(Registrant's telephone number, including area code)

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
-

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act  
(17 CFR 240.13e-4(c))

---

Item 8.01. Other Events.

On June 2, 2011, NovaDel Pharma Inc., a Delaware corporation (the “Company”) announced that the Company opened an original Investigational New Drug application with the United States Food and Drug Administration for its lead development program Duromist™, its sildenafil oral spray product for the treatment of erectile dysfunction.

The full text of the press release is set forth in Exhibit 99.1 hereto and incorporated herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
----------------	-------------

99.1	Press Release of NovaDel Pharma Inc. dated June 2, 2011, titled “NovaDel Reports Opening of Duromist™ original IND with FDA.”
------	---

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovaDel Pharma Inc.

By: /s/ Steven B. Ratoff  
Name: Steven B. Ratoff  
Title: President and Chief  
Executive Officer

Date: June 2, 2011

---

